Perrigo Company plc (NYSE:PRGO) Stock Holdings Increased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lifted its stake in Perrigo Company plc (NYSE:PRGO) by 9.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,149 shares of the company’s stock after purchasing an additional 1,968 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Perrigo were worth $595,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Price T Rowe Associates Inc. MD lifted its position in shares of Perrigo by 6,828.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,845,539 shares of the company’s stock worth $201,710,000 after purchasing an additional 7,732,309 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Perrigo by 0.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,989,530 shares of the company’s stock worth $179,698,000 after purchasing an additional 27,835 shares in the last quarter. Deprince Race & Zollo Inc. lifted its position in shares of Perrigo by 1.1% in the fourth quarter. Deprince Race & Zollo Inc. now owns 4,557,844 shares of the company’s stock worth $117,182,000 after purchasing an additional 50,728 shares in the last quarter. Cooke & Bieler LP lifted its position in shares of Perrigo by 4.1% in the fourth quarter. Cooke & Bieler LP now owns 3,573,651 shares of the company’s stock worth $91,879,000 after purchasing an additional 139,650 shares in the last quarter. Finally, Ion Asset Management Ltd. lifted its position in shares of Perrigo by 50.1% in the fourth quarter. Ion Asset Management Ltd. now owns 2,820,000 shares of the company’s stock worth $72,502,000 after purchasing an additional 941,667 shares in the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday, May 24th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $33.00.

Perrigo Price Performance

Shares of PRGO opened at $27.41 on Thursday. The firm has a market cap of $3.77 billion, a PE ratio of -23.43 and a beta of 0.46. The firm’s 50 day moving average price is $25.96 and its 200 day moving average price is $26.17. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. Perrigo Company plc has a twelve month low of $23.14 and a twelve month high of $30.93.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.04. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the firm earned $0.29 earnings per share. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. As a group, research analysts expect that Perrigo Company plc will post 2.56 EPS for the current fiscal year.

Perrigo Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 17th. Investors of record on Friday, May 30th will be paid a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 4.23%. The ex-dividend date of this dividend is Friday, May 30th. Perrigo’s payout ratio is presently -88.55%.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.